Design and Baseline Characteristics of the STRIDE Trial: evaluating Semaglutide in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes

医学 2型糖尿病 赛马鲁肽 临床终点 内科学 安慰剂 不利影响 人口 随机对照试验 血糖性 物理疗法 冠状动脉疾病 糖尿病 胰岛素 内分泌学 病理 替代医学 环境卫生 利拉鲁肽
作者
Marc P. Bonaca,Andrei‐Mircea Catarig,Yasemin Hansen,Kim Houlind,Chethana Ramesh,Bernhard Ludvik,Joakim Nordanstig,Neda Rasouli,Harald Sourij,Subodh Verma
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy [Oxford University Press]
标识
DOI:10.1093/ehjcvp/pvae071
摘要

Abstract Background People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycemic control, reduce body weight and reduce the risk of major adverse cardiovascular events, in people with atherosclerotic cardiovascular disease and type 2 diabetes (T2D). Methods STRIDE (NCT04560998) is a randomized, placebo-controlled, double-blind phase 3b trial evaluating 1 mg once-weekly subcutaneous semaglutide (GLP-1 RA) vs. placebo, in people with symptomatic PAD (Fontaine IIa claudication) and T2D. Eligible participants were ≥ 18 years, had hemodynamically stable PAD, had no planned intervention, and were not receiving a GLP-1 RA. The primary endpoint is change in maximum walking distance on a constant-load treadmill (CLT). Secondary endpoints include quality of life and cardiometabolic assessments. Results A total of 792 participants were randomized in 20 countries. Participants’ median age was 68 and they had T2D for a median of 12 years. Risk factors included 25.6% current smokers, 87.9% with hypertension, and 42.7% with coronary heart disease. The mean BMI was 29.6 kg/m2 and mean HbA1C was 7.3%. Participants exhibited baseline functional impairment with a median maximum walking distance of 186 meters on a CLT. Conclusion STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lxx发布了新的文献求助10
刚刚
研友_pnxNq8完成签到,获得积分10
刚刚
刚刚
轻松的冬瓜完成签到 ,获得积分10
刚刚
1秒前
SciGPT的应助被阔达碧琴采纳,获得10
1秒前
Jasper的应助被调皮的香寒采纳,获得10
1秒前
NexusExplorer的应助被Code_king采纳,获得10
2秒前
q2026发布了新的文献求助10
2秒前
tingfengdemao完成签到,获得积分10
2秒前
cdercder的应助被smh采纳,获得10
2秒前
Lilililili完成签到,获得积分10
2秒前
奋斗的绝悟完成签到,获得积分10
3秒前
417777完成签到,获得积分10
3秒前
sh完成签到,获得积分10
3秒前
3秒前
CipherSage的应助被海绵采纳,获得10
4秒前
4秒前
你好发布了新的文献求助10
4秒前
充电宝的应助被橘子采纳,获得10
4秒前
5秒前
乐乐的应助被鸢一折纸采纳,获得10
5秒前
5秒前
5秒前
5秒前
赵杨发布了新的文献求助10
5秒前
yetong发布了新的文献求助10
5秒前
6秒前
6秒前
YY完成签到,获得积分10
6秒前
琦_完成签到,获得积分10
6秒前
7秒前
7秒前
cc完成签到,获得积分10
7秒前
小二郎的应助被腈仙采纳,获得10
7秒前
记住星辰完成签到,获得积分10
7秒前
wanci的应助被曹雪采纳,获得10
7秒前
7秒前
在水一方的应助被讨厌科研采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522